Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propanol SCHEMBL7178295 | 0.93 | CHRNB2 (0.43) | CHRNB2CHRNA4NPC1RAB9ALMNA | |
| SCHEMBL7924171 | 0.91 | MAPT (0.47) | CHRNB2CHRNA4LMNACYP1A2CYP3A4 | |
| SCHEMBL1557490 | 0.89 | GGPS1 (0.49) | CHRNB2CHRNA4NPC1RAB9ACYP3A4 | |
| SCHEMBL27880039 | 0.87 | GGPS1 (0.51) | CHRNB2CHRNA4 | |
| SCHEMBL19668758 | 0.86 | CHRNB2 (0.46) | CHRNB2CHRNA4NPC1RAB9A | |
| SCHEMBL188568 | 0.84 | CHRNB2 (0.49) | CHRNB2CHRNA4 | |
| SCHEMBL21968171 | 0.83 | NPC1 (0.45) | CHRNB2CHRNA4NPC1RAB9ALMNA | |
| SCHEMBL30174297 | 0.83 | CHRNB2 (0.49) | CHRNB2CHRNA4NPC1RAB9ALMNA | |
| SCHEMBL428322 | 0.83 | CHRNB2 (0.49) | CHRNB2CHRNA4NPC1RAB9ALMNA | |
| SCHEMBL17841473 | 0.82 | CHRNB2 (0.46) | CHRNB2CHRNA4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142546-A1 | RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING | THE ASAN FOUNDATION (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230129721-A1 | STABILIZER FOR RADIOPHARMACEUTICALS AND RADIOPHARMACEUTICAL COMPOSITION COMPRISING THE SAME | THE ASAN FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| EP-3808739-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3309152-B1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMA (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10183933-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-22 | — | — | US | disclosed |
| EP-3309152-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2516417-B1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMA (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2017-09-14 | — | — | US | disclosed |
| US-9676759-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-06-13 | — | — | US | disclosed |
| CN-101357915-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2009-02-04 | — | — | CN | disclosed |
| CN-100430398-C | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2008-11-05 | — | — | CN | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| CN-100355755-C | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2007-12-19 | — | — | CN | disclosed |
| CN-1765899-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2006-05-03 | — | — | CN | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| CN-1440410-A | Diazabicyclic central nervous system active agents | ABBOTT LAB (US) | 2003-09-03 | — | — | CN | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | CHRNB2 10/4885CHRNA4 11/4885NPC1 408/4885 |
| US-20230142546-A1 | RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING | SERPINC1, F3, F11 | CHRNB2 4777/4885CHRNA4 4853/4885NPC1 901/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885NPC1 333/4885 |
| US-20230129721-A1 | STABILIZER FOR RADIOPHARMACEUTICALS AND RADIOPHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GC, ADORA2B, TBCB | CHRNB2 2948/4885CHRNA4 4111/4885NPC1 238/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885NPC1 333/4885 |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | CHRNB2 4051/4885CHRNA4 4409/4885NPC1 802/4885 |
| US-10183933-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | PIK3CD, PIK3CA, PIK3R5 | CHRNB2 4051/4885CHRNA4 4409/4885NPC1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.